KalVista Pharmaceuticals (KALV) Tops Q2 EPS by 16c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.90), $0.16 better than the analyst estimate of ($1.06).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• On Holding AG (ONON) Stock: Market Doesn't Appreciate Brand's Potential, Says Analyst
• AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print